X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs DR. REDDYS LAB - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD DR. REDDYS LAB ORCHID PHARMA LTD/
DR. REDDYS LAB
 
P/E (TTM) x -0.7 27.6 - View Chart
P/BV x 0.5 2.8 16.7% View Chart
Dividend Yield % 0.0 1.0 -  

Financials

 ORCHID PHARMA LTD   DR. REDDYS LAB
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
DR. REDDYS LAB
Mar-16
ORCHID PHARMA LTD/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1944,383 4.4%   
Low Rs352,750 1.3%   
Sales per share (Unadj.) Rs276.5920.1 30.0%  
Earnings per share (Unadj.) Rs-79.2126.1 -62.8%  
Cash flow per share (Unadj.) Rs-43.5183.0 -23.7%  
Dividends per share (Unadj.) Rs020.00 0.0%  
Dividend yield (eoy) %00.6 0.0%  
Book value per share (Unadj.) Rs53.9685.8 7.9%  
Shares outstanding (eoy) m70.45170.61 41.3%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x0.43.9 10.7%   
Avg P/E ratio x-1.428.3 -5.1%  
P/CF ratio (eoy) x-2.619.5 -13.5%  
Price / Book Value ratio x2.15.2 40.8%  
Dividend payout %015.9 0.0%   
Avg Mkt Cap Rs m8,067608,481 1.3%   
No. of employees `0002.821.7 12.9%   
Total wages/salary Rs m2,52731,874 7.9%   
Avg. sales/employee Rs Th6,956.17,244.4 96.0%   
Avg. wages/employee Rs Th902.51,470.9 61.4%   
Avg. net profit/employee Rs Th-1,993.0992.8 -200.7%   
INCOME DATA
Net Sales Rs m19,477156,978 12.4%  
Other income Rs m4072,693 15.1%   
Total revenues Rs m19,884159,671 12.5%   
Gross profit Rs m1,10334,587 3.2%  
Depreciation Rs m2,5199,705 26.0%   
Interest Rs m5,227824 634.3%   
Profit before tax Rs m-6,23626,751 -23.3%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-1255,237 -2.4%   
Profit after tax Rs m-5,58021,514 -25.9%  
Gross profit margin %5.722.0 25.7%  
Effective tax rate %2.019.6 10.3%   
Net profit margin %-28.713.7 -209.1%  
BALANCE SHEET DATA
Current assets Rs m11,014118,201 9.3%   
Current liabilities Rs m32,06068,368 46.9%   
Net working cap to sales %-108.131.7 -340.4%  
Current ratio x0.31.7 19.9%  
Inventory Days Days9560 158.2%  
Debtors Days Days3497 34.6%  
Net fixed assets Rs m29,44072,265 40.7%   
Share capital Rs m705853 82.6%   
"Free" reserves Rs m2,043111,548 1.8%   
Net worth Rs m3,800117,009 3.2%   
Long term debt Rs m9,01810,690 84.4%   
Total assets Rs m46,510200,104 23.2%  
Interest coverage x-0.233.5 -0.6%   
Debt to equity ratio x2.40.1 2,597.6%  
Sales to assets ratio x0.40.8 53.4%   
Return on assets %-0.811.2 -6.8%  
Return on equity %-146.918.4 -798.7%  
Return on capital %-3.721.6 -17.3%  
Exports to sales %37.946.3 81.9%   
Imports to sales %22.69.0 252.8%   
Exports (fob) Rs m7,37872,618 10.2%   
Imports (cif) Rs m4,40614,050 31.4%   
Fx inflow Rs m7,51375,405 10.0%   
Fx outflow Rs m5,64927,115 20.8%   
Net fx Rs m1,86548,290 3.9%   
CASH FLOW
From Operations Rs m1,68240,476 4.2%  
From Investments Rs m-9,860-19,421 50.8%  
From Financial Activity Rs m6,644-17,009 -39.1%  
Net Cashflow Rs m-1,5354,046 -37.9%  

Share Holding

Indian Promoters % 32.3 25.5 126.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 5.4 85.2%  
FIIs % 3.3 35.3 9.3%  
ADR/GDR % 4.6 18.5 24.9%  
Free float % 55.3 15.3 361.4%  
Shareholders   84,811 75,885 111.8%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   STERLING BIOTECH  SANOFI INDIA  ALEMBIC PHARMA  SUN PHARMA  NOVARTIS  

Compare ORCHID PHARMA LTD With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Recovery of Global Markets, Apex Frozen Food IPO & Cues to Watch Out Today(Pre-Open)

Indian stock markets remained range-bound in lacklustre trade on Tuesday as market participants kept to the sidelines in the absence of clear triggers.

Related Views on News

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

Sep 12, 2016

Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Aug 23, 2017 09:39 AM

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 8-QTR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS